AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9848044 — intervention group
Group type: COMPARATOR
Intervention: Autograft alone (control)
Number of subjects: 6
Study 8033956 — intervention group
Group type: EXPERIMENTAL
Intervention: Benserazide (inhibition of DOPA decarboxylase)
Number of subjects: 0
Study 8033956 — intervention group
Group type: COMPARATOR
Intervention: Control (without benserazide)
Number of subjects: 0
Study 8033956 — intervention group
Group type: EXPERIMENTAL
Intervention: Benserazide
Number of subjects: 0
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M1 (less than 5% blasts)
Number of subjects: 2516
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M2 (4% to 25% blasts)
Number of subjects: 2516
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M3 (greater than 25% blasts)
Number of subjects: 2516
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M1 after late randomization
Number of subjects: 2516
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M2 after late randomization
Number of subjects: 2516
Study 2685179 — intervention group
Group type: EXPERIMENTAL
Intervention: d14 BM M3 after late randomization
Number of subjects: 2516
Study 557329 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation provocation tests with formalin
Number of subjects: 28
Study 557329 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to formalin
Number of subjects: 28
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+fluoride
Number of subjects: 120
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+CPP‐ACP
Number of subjects: 120
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+CPP‐ACP+fluoride
Number of subjects: 120
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin
Number of subjects: 120
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin+fluoride
Number of subjects: 120
Study 31582598 — intervention group
Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin+CPP‐ACP
Number of subjects: 120
Study 31582598 — intervention group
Group type: COMPARATOR
Intervention: blank control
Number of subjects: 120
Study 31582598 — intervention group
Group type: COMPARATOR
Intervention: irradiation control
Number of subjects: 120
Study 30851499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane (ESP) block with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Number of subjects: 60
Study 30851499 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guided Quadratus Lumborum Block (QLB) with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Number of subjects: 60
Study 30851499 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 60
Study 30851499 — intervention group
Group type: COMPARATOR
Intervention: QLB block
Number of subjects: 60
Study 29138131 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS+CR (Clinician Report)
Number of subjects: 235
Study 29138131 — intervention group
Group type: COMPARATOR
Intervention: CHESS-Only
Number of subjects: 235
Study 26506582 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (GXR) 1-7 mg per day
Number of subjects: 314
Study 26506582 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (GXR)
Number of subjects: 314
Study 26506582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 22974284 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulation (CCT T8) with core tablet (C8) and mannitol, lag time of 6 hrs before immediate release of drug.
Number of subjects: 0
Study 22974284 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized solid dispersion (S9) used for formulating optimized core tablet formulation (C8).
Number of subjects: 0
Study 21300933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus CAPIRI (irinotecan 200 mg/m(2), capecitabine 800 mg/m(2) twice daily)
Number of subjects: 185
Study 21300933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus CAPOX (oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2) twice daily)
Number of subjects: 185
Study 19904601 — intervention group
Group type: EXPERIMENTAL
Intervention: GIII series (Vitrolife)
Number of subjects: 512
Study 19904601 — intervention group
Group type: COMPARATOR
Intervention: ISM (Medicult)
Number of subjects: 512
Study 16989024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied 5 or 7 days a week for six weeks
Number of subjects: 724
Study 16989024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied 5 times a week
Number of subjects: 724
Study 16989024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied daily
Number of subjects: 724
Study 16989024 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-comparative trial with imiquimod
Number of subjects: 724
Study 16989024 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision (standard treatment)
Number of subjects: 724
Study 12628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MA) 160 mg (8 mL)
Number of subjects: 67
Study 12628884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution 8 mL)
Number of subjects: 67
Study 12628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MA)
Number of subjects: 67
Study 12628884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 67
Study 10977039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/orally for 3 months)
Number of subjects: 29
Study 10977039 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29
Study 9091333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimbrioplasty and salpingostomy
Number of subjects: 0
Study 9091333 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingostomy
Number of subjects: 0
Study 9091333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingostomy
Number of subjects: 0
Study 9091333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimbrioplasty
Number of subjects: 0
Study 8165613 — intervention group
Group type: EXPERIMENTAL
Intervention: Textarin/Ecarin test system
Number of subjects: 0
Study 8165613 — intervention group
Group type: EXPERIMENTAL
Intervention: Textarin with polybrene
Number of subjects: 0
Study 8165613 — intervention group
Group type: COMPARATOR
Intervention: Factor V deficiency and specific inhibitors of factor V
Number of subjects: 0
Study 3752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation without glycopyrronium
Number of subjects: 100
Study 3752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously breathing without glycopyrronium
Number of subjects: 100
Study 3752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation with glycopyrronium (7.5 micrograms/kg)
Number of subjects: 100
Study 3752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously breathing with glycopyrronium (7.5 micrograms/kg)
Number of subjects: 100
Study 31043093 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness-education intervention over 8 weeks
Number of subjects: 138
Study 31043093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wellness-education intervention)
Number of subjects: 138
Study 30518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese version of the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 1075
Study 30518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis of the EPDS
Number of subjects: 1075
Study 30518774 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS
Number of subjects: 1075
Study 26649879 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (mobile phone app plus Fitbit)
Number of subjects: 30
Study 26649879 — intervention group
Group type: COMPARATOR
Intervention: Control (Fitbit)
Number of subjects: 30
Study 26649879 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 30
Study 24656153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg generic formulation (test)
Number of subjects: 24
Study 24656153 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation (reference)
Number of subjects: 24
Study 24656153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 22176850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder group (n=1374)
Number of subjects: 3618
Study 22176850 — intervention group
Group type: COMPARATOR
Intervention: No reminder group
Number of subjects: 3618
Study 22176850 — intervention group
Group type: EXPERIMENTAL
Intervention: Undeliverable reminder group
Number of subjects: 3618
Study 20391081 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate-electrolyte solution
Number of subjects: 10
Study 20391081 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (8 ml x kg BM(‐1))
Number of subjects: 10
Study 20391081 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study 17922561 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2mg/70kg
Number of subjects: 0
Study 17922561 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4mg/70kg
Number of subjects: 0
Study 17922561 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (continuous infusion)
Number of subjects: 0
Study 15988430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention conducted by peer educators (20-minute semiscripted interview)
Number of subjects: 295
Study 15988430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 295
Study 15988430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 295
Study 15988430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study 12706638 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin-sodium (low molecular weight heparin), administered twice daily.
Number of subjects: 158
Study 12706638 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 158
Study 10637141 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning
Number of subjects: 1200
Study 10637141 — intervention group
Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 1200
Study 9122553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 12
Study 9122553 — intervention group
Group type: COMPARATOR
Intervention: Solitary-sleeping
Number of subjects: 12
Study 1912675 — intervention group
Group type: EXPERIMENTAL
Intervention: First chemotherapy (105 women)
Number of subjects: 206
Study 1912675 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (64 women)
Number of subjects: 206
Study 1912675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation by 64 women one year after treatment
Number of subjects: 206
Study 1912675 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (78 women)
Number of subjects: 206
Study 6874413 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower seed oil (60 ml/d)
Number of subjects: 6
Study 6874413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (900 mg)
Number of subjects: 6
Study 6874413 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 6
Study 30831478 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized modular treatment based on cognitive-behavioral therapy
Number of subjects: 32
Study 27780895 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized lung cancer risk projections calculated using the LLP risk model
Number of subjects: 513
Study 27523719 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 180 μg
Number of subjects: 15
Study 27523719 — intervention group
Group type: COMPARATOR
Intervention: Albuterol HFA 180 μg
Number of subjects: 15
Study 27523719 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI and HFA
Number of subjects: 15
Study 24158227 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 839
Study 24158227 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 839
Study 24158227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (8-week treatment)
Number of subjects: 839
Study 22999073 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab treatment in group A (additional platelet inhibition)
Number of subjects: 130
Study 22999073 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation with heparin in group C1 (control group)
Number of subjects: 130
Study 22999073 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation with heparin in group C2 (control group)
Number of subjects: 130
Study 20393175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab + azathioprine)
Number of subjects: 508
Study 20393175 — intervention group
Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 508
Study 20393175 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 508
Study 17678774 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographic method (calculated depth based on landmarks)
Number of subjects: 100
Study 17678774 — intervention group
Group type: COMPARATOR
Intervention: 15-cm fixed length
Number of subjects: 100
Study 16282139 — intervention group
Group type: EXPERIMENTAL
Intervention: Rawls' theory of justice
Number of subjects: 0
Study 12351526 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of GnRH agonist administration for 1 week after hCG injection
Number of subjects: 138
Study 12351526 — intervention group
Group type: COMPARATOR
Intervention: Elective cryopreservation of all pronucleate embryos
Number of subjects: 138
Study 10540091 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg x kg‐1 (group R3)
Number of subjects: 60
Study 10540091 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 microg x kg‐1 (group R4)
Number of subjects: 60
Study 10540091 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 5 microg x kg‐1 (group R5)
Number of subjects: 60
Study 7776303 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpable uterine artery pulsation
Number of subjects: 299
Study 7776303 — intervention group
Group type: COMPARATOR
Intervention: No palpable uterine artery pulsation
Number of subjects: 299
Study 2153780 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic‐based instruction (ABI)
Number of subjects: 55
Study 2153780 — intervention group
Group type: COMPARATOR
Intervention: Teacher‐directed instruction (TDI)
Number of subjects: 55
Study 7423170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (220 mg, three daily doses)
Number of subjects: 87
Study 7423170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 31958000 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming program for 10 weeks
Number of subjects: 40
Study 31958000 — intervention group
Group type: COMPARATOR
Intervention: No exercise program (control group)
Number of subjects: 40
Study 30448193 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (SPN)
Number of subjects: 23
Study 30448193 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued enteral nutrition)
Number of subjects: 23
Study 28873109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin cream 0.3% once daily
Number of subjects: 629
Study 28873109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin cream 1% once or twice daily
Number of subjects: 629
Study 28873109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin gel 1% twice daily
Number of subjects: 629
Study 28873109 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 629
Study 27313086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine group (six courses of alternating R-CHOP or R-DHAP followed by high-dose cytarabine-containing conditioning regimen and ASCT)
Number of subjects: 497
Study 27313086 — intervention group
Group type: COMPARATOR
Intervention: Control group (six courses of R-CHOP followed by myeloablative radiochemotherapy and ASCT)
Number of subjects: 497
Study 27313086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine group
Number of subjects: 497
Study 27313086 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 497
Study 25019551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice quality
Number of subjects: 43
Study 25019551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice time
Number of subjects: 43
Study 25019551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice quality and time
Number of subjects: 43
Study 22546988 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine (ABC/3TC)
Number of subjects: 244
Study 22546988 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 244
Study 22546988 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 244
Study 22546988 — intervention group
Group type: COMPARATOR
Intervention: atazanavir/ritonavir (ATV/r)
Number of subjects: 244
Study 19616668 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day
Number of subjects: 102
Study 19616668 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day, up titrated to 10 mg/day
Number of subjects: 102
Study 19616668 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 102
Study 19616668 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 102
Study 17135223 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 14759940 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicultural smoking prevention curriculum
Number of subjects: 1430
Study 14759940 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 1430
Study 11401925 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg daily for 1 year)
Number of subjects: 20
Study 9479360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy with tularemia booster (TB) and anticoagulant treatment (fibrinolysin, pelentan, and aspirin)
Number of subjects: 97
Study 9479360 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (control group 1)
Number of subjects: 97
Study 9479360 — intervention group
Group type: COMPARATOR
Intervention: TB inoculation without anticoagulants (control group 2)
Number of subjects: 97
Study 8200552 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (n = 5)
Number of subjects: 15
Study 8200552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 15
Study 3604886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Number of subjects: 23
Study 3604886 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar cathodal noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Number of subjects: 23
Study 3604886 — intervention group
Group type: COMPARATOR
Intervention: Bipolar noncapturing conditioning stimuli (Sc) delivered 3 mm away from pacing stimuli
Number of subjects: 23
Study 3604886 — intervention group
Group type: COMPARATOR
Intervention: Unipolar noncapturing conditioning stimuli (Sc) delivered 3 mm away from pacing stimuli
Number of subjects: 23
Study 3604886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar conditioning stimuli delivered during circus movement tachycardia
Number of subjects: 23
Study 29718968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation (0.3 g·kg‐1 body weight)
Number of subjects: 8
Study 29718968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29718968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation during 10-week resistance training
Number of subjects: 8
Study 28473520 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable menstrual cup
Number of subjects: 604
Study 28473520 — intervention group
Group type: COMPARATOR
Intervention: Monthly sanitary pads
Number of subjects: 604
Study 28473520 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (controls)
Number of subjects: 604
Study 25732222 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 125 ml ONS (2.4 kcal/ml)/d for 12 weeks
Number of subjects: 87
Study 25732222 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual care
Number of subjects: 87
Study 24269911 — intervention group
Group type: EXPERIMENTAL
Intervention: Join2move intervention (self-paced 9-week PA program)
Number of subjects: 199
Study 24269911 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 199
Study 20978528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat yogurt supplement
Number of subjects: 11
Study 20978528 — intervention group
Group type: COMPARATOR
Intervention: Low-fat yogurt supplement
Number of subjects: 11
Study 18718556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 18718556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12965979 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with ACE inhibitors
Number of subjects: 1860
Study 12965979 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy without ACE inhibitors
Number of subjects: 1860
Study 12965979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure levels
Number of subjects: 1860
Study 12965979 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure less than 110 mm Hg
Number of subjects: 1860
Study 10220792 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID/ASA-induced erosions without Hp gastritis
Number of subjects: 122
Study 10220792 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID/ASA-induced erosions with concomitant Hp gastritis
Number of subjects: 122